Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIOGBU)

• Drug Name: Bosentan Drug Info
• Synonyms: Actelion; Bosentanum; Tracleer; Bosentan (INN); KS-5062; Ro 47-0203; Tracleer (TN); Bosentan [USAN:INN:BAN]; Ro 47-0203/039; Ro-47-0203; Ro-47-0203/029; Ro-47-0203/039; P-tert-Butyl-N-[6-(2-hydroxyethoxy); P-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide; 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide; 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide; 4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Pulmonary arterial hypertension	BB01.0	Approved	[1]
Pulmonary hypertension	BB01	Approved	[2]
Scleroderma	4A42	Investigative	[2]

• Therapeutic Class: Antihypertensive Agents
• Cross-matching ID:
  PubChem CID: 104865
  ChEBI ID: CHEMBL957
  CAS Number: CAS 147536-97-8
  TTD Drug ID: DMIOGBU
  VARIDT Drug ID: DR00288
  INTEDE Drug ID: DR0222
  ACDINA Drug ID: D00074

Molecule-Related Drug Atlas

Drug(s) Targeting Endothelin A receptor (EDNRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ambrisentan	DMD1QXW	Pulmonary arterial hypertension	BB01.0	Approved	[9]
Macitentan	DMP79A1	Cardiovascular disease	BA00-BE2Z	Approved	[10]
Sparsentan	DMMP51W	IgA nephropathy	MF8Y	Approved	[11]
LU302146	DMMJVXZ	Pulmonary hypertension	BB01	Approved	[12]
Atrasentan	DMM74PK	Diabetic nephropathy	GB61.Z	Phase 3	[13]
Clazosentan	DMQSBX4	Cerebral vasospasm	BA85.Z	Phase 3	[14]
PF-1228305	DMS1EQ7	Pulmonary hypertension	BB01	Phase 3	[15]
Darusentan	DMN8DQH	Hypotension	BA20-BA21	Phase 3	[16]
BQ-123	DM0MO8I	Pulmonary arterial hypertension	BB01.0	Phase 2	[17]
FR139317	DMEL5SV	Hypertension	BA00-BA04	Phase 2	[18]

Drug(s) Targeting Endothelin B receptor (EDNRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Macitentan	DMP79A1	Cardiovascular disease	BA00-BE2Z	Approved	[10]
BQ788	DM6KRLW	Acute kidney injury	GB60	Phase 3	[19]
PD-145065	DMWVBTQ	Hypertension	BA00-BA04	Phase 2	[20]
SPI-1620	DMNPRMC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[21]
ENB003	DMK2B3S	Melanoma	2C30	Phase 1/2	[22]
J-104132	DM5E6MK	Pulmonary arterial hypertension	BB01.0	Discontinued in Phase 2	[23]
ENRASENTAN	DM05F1Z	Pulmonary arterial hypertension	BB01.0	Discontinued in Phase 2	[24]
SB-209670	DMJYW80	Arrhythmia	BC9Z	Discontinued in Phase 2	[25]
ET-1	DMA85ND	N. A.	N. A.	Phase 0	[26]
PD142893	DMFA27N	N. A.	N. A.	Terminated	[27]

Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[28]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[29]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[30]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[31]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[30]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[32]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[33]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[34]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[35]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[32]

Drug(s) Transported By Organic anion transporting polypeptide 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[36]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[30]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[37]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[38]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[30]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[39]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[33]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[35]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[40]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[35]

Drug(s) Transported By Organic anion transporting polypeptide 2B1 (SLCO2B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[41]
L-Glutamic Acid	DM4PUDW	Schizophrenia	6A20	Approved	[42]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[43]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[31]
Pravastatin	DM6A0X7	Adult acute monocytic leukemia		Approved	[44]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[45]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[46]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[47]
Digoxin	DMQCTIH	Arrhythmia	BC9Z	Approved	[48]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[49]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[50]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[51]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[52]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[53]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[54]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[55]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[56]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[57]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[51]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[58]

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[59]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[60]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[61]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[62]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[63]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[62]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[64]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[65]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]

Drug(s) Affected By Solute carrier organic anion transporter family member 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[68]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[69]
Repaglinide	DM5SXUV	Diabetic complication	5A2Y	Approved	[70]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[71]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[72]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[73]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[73]
Hydroxyurea	DMOQVU9	Chronic myelogenous leukaemia	2A20.0	Approved	[74]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[75]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[76]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[77]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[78]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[78]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[77]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[78]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[79]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[77]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[80]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[77]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[81]

Drug(s) Affected By Serine/threonine-protein kinase DCLK1 (DCLK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[82]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[83]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[86]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[87]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[88]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[89]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[90]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[91]

Drug(s) Affected By Kynurenine 3-monooxygenase (KMO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[92]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[93]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[95]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[89]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[96]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[97]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[98]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[99]

Drug(s) Affected By Carbonic anhydrase 12 (CA12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[100]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[101]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[82]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[101]
Topiramate	DM82Z30	Alcohol dependence	6C40.2	Approved	[103]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[104]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[105]

Drug(s) Affected By All-trans-retinol dehydrogenase ADH1B (ADH1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[106]
Selenium	DM25CGV	N. A.	N. A.	Approved	[107]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[108]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[109]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[87]
Flucloxacillin	DMNUWST	Bacterial infection	1A00-1C4Z	Approved	[110]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[84]

Drug(s) Affected By Alcohol dehydrogenase 1C (ADH1C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[111]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[112]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[113]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[114]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[113]
Acocantherin	DM7JT24	Atrial fibrillation	BC81.3	Approved	[115]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[95]

Drug(s) Affected By Complement component C9 (C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[99]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[116]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[117]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[118]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[119]
3R14S-OCHRATOXIN A	DM2KEW6	Discovery agent	N.A.	Investigative	[120]

Drug(s) Affected By Superoxide dismutase , mitochondrial (SOD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[121]
Selenium	DM25CGV	N. A.	N. A.	Approved	[122]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[123]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[124]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[125]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[126]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[127]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[112]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[128]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[129]

Drug(s) Affected By Fructose-bisphosphate aldolase B (ALDOB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[112]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[130]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[95]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[131]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[133]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[84]

Drug(s) Affected By Amino acid transporter heavy chain SLC3A2 (SLC3A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[107]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[134]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[136]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[137]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[138]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[139]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[138]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[140]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[141]

Drug(s) Affected By All-trans-retinol dehydrogenase ADH4 (ADH4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[95]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[95]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[142]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[90]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[84]

Drug(s) Affected By Glutathione S-transferase theta-2 (GSTT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[143]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[144]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[133]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[145]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[146]
Artesunate	DMR27C8	Infection of P. falciparum	1F40	Approved	[147]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[148]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[149]

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[150]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[151]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[152]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[153]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[154]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[155]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[156]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[157]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[158]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[156]

Drug(s) Affected By 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 (HSD3B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[99]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[159]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[160]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[160]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[161]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[162]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[144]
Hexachlorophene	DMLKSE0	Bacterial infection	1A00-1C4Z	Approved	[163]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[164]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[102]

Drug(s) Affected By Tyrosine aminotransferase (TAT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[165]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[166]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[109]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[167]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[168]
Miconazole	DMPMYE8	Cutaneous candidiasis	1F23.14	Approved	[169]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[170]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[171]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[84]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[172]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[173]
Methysergide	DM1EF73	Migraine	8A80	Approved	[79]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[174]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[79]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[112]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[176]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[113]

Drug(s) Affected By Macrophage mannose receptor 1 (MRC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Valsartan	DMREUQ6	Chronic heart failure	BD1Z	Approved	[177]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[178]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[179]
CYCLOPAMINE	DMEM2SW	Discovery agent	N.A.	Investigative	[180]

Drug(s) Affected By G0/G1 switch protein 2 (G0S2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Selenium	DM25CGV	N. A.	N. A.	Approved	[122]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[181]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[83]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[182]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[93]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[109]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]

Drug(s) Affected By Carbamoyl-phosphate synthase , mitochondrial (CPS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[183]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[184]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[185]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[86]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[95]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[186]
Flucloxacillin	DMNUWST	Bacterial infection	1A00-1C4Z	Approved	[110]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]

Drug(s) Affected By Glucose-6-phosphatase catalytic subunit 1 (G6PC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[187]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[188]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[189]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[190]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[95]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[95]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[191]

Drug(s) Affected By Achaete-scute homolog 1 (ASCL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[192]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[105]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[193]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[82]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[194]
Afimoxifene	DMFORDT	Breast cancer	2C60-2C65	Phase 2	[195]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[119]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[196]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[197]
Propanoic Acid	DM9TN2W	Discovery agent	N.A.	Investigative	[198]

Drug(s) Affected By Microsomal triglyceride transfer protein large subunit (MTTP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[199]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[199]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[200]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[199]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[199]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[200]
Tolcapone	DM8MNVO	Parkinson disease	8A00.0	Approved	[201]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[202]

Drug(s) Affected By Inhibin beta E chain (INHBE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[203]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[204]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[203]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[203]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[203]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[205]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[203]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[82]

Drug(s) Affected By Metallothionein-1X (MT1X)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[206]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[207]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[208]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[184]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[139]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[209]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[160]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[160]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[109]

Drug(s) Affected By Complement factor H-related protein 3 (CFHR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[210]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[211]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[98]

Drug(s) Affected By Nuclear factor 1 X-type (NFIX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[212]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[92]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[140]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[213]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[144]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[214]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[210]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[215]

Drug(s) Affected By Phosphoenolpyruvate carboxykinase , mitochondrial (PCK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[134]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[216]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[217]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[182]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[135]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[218]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[86]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[219]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[220]

Drug(s) Affected By Organic solute transporter subunit alpha (SLC51A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[174]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[221]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[112]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[92]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[222]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[221]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[93]

Drug(s) Affected By Organic solute transporter subunit beta (SLC51B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[153]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[221]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[112]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[222]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[189]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[221]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[223]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[109]

Drug(s) Affected By Liver-expressed antimicrobial peptide 2 (LEAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[109]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[224]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[95]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[225]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[96]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[84]

Drug(s) Affected By N-acetylmuramoyl-L-alanine amidase (PGLYRP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[215]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[90]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[84]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[98]
Milchsaure	DM462BT	Pruritus	EC90	Investigative	[226]

Drug(s) Affected By Bile acid receptor (NR1H4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[227]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[228]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[221]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[229]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[230]
Nisoldipine	DM7ISKJ	Hypertension	BA00-BA04	Approved	[228]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[221]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[231]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]

Drug(s) Affected By Normal mucosa of esophagus-specific gene 1 protein (C15ORF48)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[114]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[232]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[182]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[94]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[105]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[233]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[133]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[234]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[235]

Drug(s) Affected By ATP-binding cassette sub-family G member 5 (ABCG5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[174]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[221]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[236]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[221]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[109]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[85]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[221]

Drug(s) Affected By Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[135]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[237]
Fructose	DM43AN2	Vomiting	MD90	Approved	[238]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[239]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[240]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[166]
Ketotifen	DM74XKS	Allergic conjunctivitis	9A60.02	Approved	[200]
Riboflavin	DM8YMWE	Acne vulgaris	ED80	Approved	[241]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[109]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[241]

Drug(s) Affected By Solute carrier family 22 member 7 (SLC22A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[242]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[175]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[137]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[243]
Allopurinol	DMLPAOB	Gout	FA25	Approved	[243]
Bumetanide	DMRV7H0	Congestive heart failure	BD10	Approved	[243]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[243]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[243]
Tetracycline	DMZA017	Acne vulgaris	ED80	Approved	[243]
Ranitidine	DM0GUSX	Gastric ulcer	DA60	Approved	[244]

Drug(s) Affected By ATP-binding cassette sub-family C member 3 (ABCC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[245]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[246]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[247]
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[248]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[249]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[250]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[102]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[251]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[252]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[253]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[254]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[255]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[256]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[257]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[258]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[259]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[260]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[261]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[262]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[260]

Drug(s) Affected By Coxsackievirus and adenovirus receptor (CXADR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[160]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[93]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[84]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[105]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[86]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[132]
Valsartan	DMREUQ6	Chronic heart failure	BD1Z	Approved	[263]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[215]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[90]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[264]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Endothelin A receptor (EDNRA)	TTKRD0G	EDNRA_HUMAN	Modulator	[3]
Endothelin B receptor (EDNRB)	TT3ZTGU	EDNRB_HUMAN	Modulator	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[4]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[4]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[5]
Cytochrome P450 2C9 (CYP2C9) Main DME	DE5IED8	CP2C9_HUMAN	Substrate	[6]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1 (HSD3B1)	OTNAZVKB	3BHS1_HUMAN	Gene/Protein Processing	[7]
Achaete-scute homolog 1 (ASCL1)	OTI4X44G	ASCL1_HUMAN	Gene/Protein Processing	[7]
Alcohol dehydrogenase 1C (ADH1C)	OTO1DV7F	ADH1G_HUMAN	Gene/Protein Processing	[7]
All-trans-retinol dehydrogenase ADH1B (ADH1B)	OTV3TB81	ADH1B_HUMAN	Gene/Protein Processing	[7]
All-trans-retinol dehydrogenase ADH4 (ADH4)	OTKDKKNG	ADH4_HUMAN	Gene/Protein Processing	[7]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Gene/Protein Processing	[7]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Gene/Protein Processing	[8]
ATP-binding cassette sub-family G member 5 (ABCG5)	OT1OMY93	ABCG5_HUMAN	Gene/Protein Processing	[7]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[8]
Bile acid receptor (NR1H4)	OTWZLPTB	NR1H4_HUMAN	Gene/Protein Processing	[7]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3494).
• [2] Bosentan FDA Label
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
• [5] Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7.
• [6] Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet. 2003;42(3):293-301.
• [7] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [8] From the Cover: MechanisticInsights in Cytotoxic and Cholestatic Potential of the Endothelial Receptor Antagonists Using HepaRG Cells. Toxicol Sci. 2017 Jun 1;157(2):451-464. doi: 10.1093/toxsci/kfx062.
• [9] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [10] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [11] Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
• [12] Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
• [13] Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S.
• [14] Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918.
• [15] Pfizer. Product Development Pipeline. March 31 2009.
• [16] Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62.
• [17] Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4.
• [18] Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem Pharmacol. 2002 Aug 1;64(3):497-505.
• [19] BQ788, an endothelin ET(B) receptor antagonist, attenuates stab wound injury-induced reactive astrocytes in rat brain. Glia. 1999 May;26(3):268-71.
• [20] Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207-13.
• [21] Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009).
• [22] ClinicalTrials.gov (NCT04205227) A Phase 1/2A Trial of ENB 003 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
• [23] Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist. J Pharmacol Exp Ther. 1999 Jun;289(3):1262-70.
• [24] Enrasentan, an antagonist of endothelin receptors. Cardiovasc Drug Rev. 2003 Spring;21(1):1-16.
• [25] Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. Br J Pharmacol. 1996 May;118(1):198-204.
• [26] IRL 2500: A potent ETB selective endothelin antagonist, Bioorg. Med. Chem. Lett. 6(19):2323-2328 (1996).
• [27] Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2704-13.
• [28] Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
• [29] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [30] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [31] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [32] The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
• [33] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [34] Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
• [35] FDA Drug Development and Drug Interactions
• [36] LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
• [37] Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
• [38] Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
• [39] Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
• [40] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
• [41] Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60.
• [42] The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
• [43] Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP. J Pharm Sci. 2017 Sep;106(9):2688-2694.
• [44] Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45.
• [45] Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
• [46] pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13.
• [47] Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006 Jul;34(7):1229-36.
• [48] Drug Interactions in Infectious Diseases.
• [49] Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 Oct;36(10):2014-23.
• [50] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [51] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [52] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [53] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [54] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [55] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [56] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [57] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [58] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [59] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [60] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [61] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [62] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [63] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [64] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [65] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [66] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [67] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [68] Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men. Clin Ther. 2011 May;33(5):655-63. doi: 10.1016/j.clinthera.2011.04.018.
• [69] Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
• [70] Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther. 2005 Jun;77(6):468-78. doi: 10.1016/j.clpt.2005.01.018.
• [71] SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients. Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.
• [72] SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008 Aug 21;359(8):789-99.
• [73] Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res. 2006 Jun;47(6):1196-202.
• [74] Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters. Exp Hematol. 2011 Apr;39(4):446-56.
• [75] Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.
• [76] Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 2009 Dec 10;27(35):5972-8.
• [77] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [78] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [79] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [80] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [81] Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
• [82] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [83] A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
• [84] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [85] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [86] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [87] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [88] Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 2006 Dec 1;66(23):11187-93. doi: 10.1158/0008-5472.CAN-06-1274.
• [89] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [90] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [91] Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
• [92] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [93] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [94] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [95] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [96] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [97] Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS One. 2011;6(7):e21920. doi: 10.1371/journal.pone.0021920. Epub 2011 Jul 6.
• [98] Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
• [99] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [100] Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors. J Med Chem. 2011 Oct 13;54(19):6905-18.
• [101] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [102] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [103] Design, synthesis, and biological evaluation of novel carbohydrate-based sulfamates as carbonic anhydrase inhibitors. J Med Chem. 2011 Mar 10;54(5):1481-9.
• [104] DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics. 2004 Apr 13;17(2):122-9. doi: 10.1152/physiolgenomics.00002.2003.
• [105] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [106] Differences in the activities of resveratrol and ascorbic acid in protection of ethanol-induced oxidative DNA damage in human peripheral lymphocytes. Food Chem Toxicol. 2012 Feb;50(2):168-74.
• [107] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [108] Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
• [109] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [110] Identification of flucloxacillin-modified hepatocellular proteins: implications in flucloxacillin-induced liver injury. Toxicol Sci. 2023 Mar 20;192(1):106-116. doi: 10.1093/toxsci/kfad015.
• [111] An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
• [112] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [113] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [114] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [115] Proteomics analysis of the proliferative effect of low-dose ouabain on human endothelial cells. Biol Pharm Bull. 2007 Feb;30(2):247-53. doi: 10.1248/bpb.30.247.
• [116] Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia. Proteomics Clin Appl. 2015 Oct;9(9-10):907-16. doi: 10.1002/prca.201400148. Epub 2015 May 15.
• [117] Fetal-sex dependent genomic responses in the circulating lymphocytes of arsenic-exposed pregnant women in New Hampshire. Reprod Toxicol. 2017 Oct;73:184-195. doi: 10.1016/j.reprotox.2017.07.023. Epub 2017 Aug 6.
• [118] Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. Toxicol Appl Pharmacol. 2009 Feb 1;234(3):345-60.
• [119] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [120] Transcriptomic alterations induced by Ochratoxin A in rat and human renal proximal tubular in vitro models and comparison to a rat in vivo model. Arch Toxicol. 2012 Apr;86(4):571-89.
• [121] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [122] Changes in gene expression profiles in response to selenium supplementation among individuals with arsenic-induced pre-malignant skin lesions. Toxicol Lett. 2007 Mar 8;169(2):162-76. doi: 10.1016/j.toxlet.2007.01.006. Epub 2007 Jan 19.
• [123] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [124] P450 3A-catalyzed O-dealkylation of lapatinib induces mitochondrial stress and activates Nrf2. Chem Res Toxicol. 2016 May 16;29(5):784-96.
• [125] Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. Free Radic Biol Med. 2001 Jan 15;30(2):148-53.
• [126] Cissus quadrangularis ethanol extract upregulates superoxide dismutase, glutathione peroxidase and endothelial nitric oxide synthase expression in hydrogen peroxide-injured human ECV304 cells. J Ethnopharmacol. 2012 Sep 28;143(2):664-72.
• [127] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [128] Manganese superoxide dismutase is a promising target for enhancing chemosensitivity of basal-like breast carcinoma. Antioxid Redox Signal. 2014 May 20;20(15):2326-46. doi: 10.1089/ars.2013.5295. Epub 2013 Nov 14.
• [129] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [130] Toxicoproteomics reveals an effect of clozapine on autophagy in human liver spheroids. Toxicol Mech Methods. 2023 Jun;33(5):401-410. doi: 10.1080/15376516.2022.2156005. Epub 2022 Dec 19.
• [131] Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12.
• [132] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [133] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [134] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [135] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [136] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [137] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [138] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [139] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [140] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [141] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [142] Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells initro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017 Jun;152(8):2022-2036.
• [143] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [144] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [145] Human drug metabolism genes in parathion-and estrogen-treated breast cells. Int J Mol Med. 2007 Dec;20(6):875-81.
• [146] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [147] Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. In Vivo. 2005 Jan-Feb;19(1):225-32.
• [148] Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma. Oncotarget. 2014 May 15;5(9):2355-71.
• [149] Influence of cell cycle on responses of MCF-7 cells to benzo[a]pyrene. BMC Genomics. 2011 Jun 29;12:333.
• [150] Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
• [151] Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
• [152] Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
• [153] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [154] Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
• [155] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [156] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [157] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [158] Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
• [159] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [160] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [161] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [162] Towards a systematic analysis of human short-chain dehydrogenases/reductases (SDR): Ligand identification and structure-activity relationships. Chem Biol Interact. 2015 Jun 5;234:114-25.
• [163] The analysis of pesticides and fungicides in the inhibition of human and rat placental 3-hydroxysteroid dehydrogenase activity: Mode of inhibition and mechanism. Toxicol Lett. 2023 Apr 15;379:76-86. doi: 10.1016/j.toxlet.2023.03.002. Epub 2023 Mar 24.
• [164] Estrogenic endocrine disruptive components interfere with calcium handling and differentiation of human trophoblast cells. J Cell Biochem. 2003 Jul 1;89(4):755-70.
• [165] Microtubule disarray in primary cultures of human hepatocytes inhibits transcriptional activity of the glucocorticoid receptor via activation of c-jun N-terminal kinase. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004 Dec;148(2):135-9.
• [166] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [167] Histone deacetylase inhibitor valproic acid promotes the differentiation of human induced pluripotent stem cells into hepatocyte-like cells. PLoS One. 2014 Aug 1;9(8):e104010.
• [168] Dexamethasone controls aryl hydrocarbon receptor (AhR)-mediated CYP1A1 and CYP1A2 expression and activity in primary cultures of human hepatocytes. Chem Biol Interact. 2009 May 15;179(2-3):288-96.
• [169] Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol. 2006 Jul;70(1):329-39.
• [170] Self-assembled 3D spheroids and hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro. Arch Toxicol. 2017 Apr;91(4):1815-1832.
• [171] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [172] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [173] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [174] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [175] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [176] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [177] Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial. PLoS One. 2012;7(6):e39930. doi: 10.1371/journal.pone.0039930. Epub 2012 Jun 29.
• [178] Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
• [179] Environmental pollutant induced cellular injury is reflected in exosomes from placental explants. Placenta. 2020 Jan 1;89:42-49. doi: 10.1016/j.placenta.2019.10.008. Epub 2019 Oct 17.
• [180] M2 macrophage-derived IL6 mediates resistance of breast cancer cells to hedgehog inhibition. Toxicol Appl Pharmacol. 2019 Feb 1;364:77-82. doi: 10.1016/j.taap.2018.12.013. Epub 2018 Dec 19.
• [181] Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood. 2007 May 15;109(10):4450-60.
• [182] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [183] Quantitative proteomic analysis of HepG2 cells treated with quercetin suggests IQGAP1 involved in quercetin-induced regulation of cell proliferation and migration. OMICS. 2009 Apr;13(2):93-103. doi: 10.1089/omi.2008.0075.
• [184] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [185] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [186] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [187] Downregulation of glucose-6-phosphatase expression contributes to fluoxetine-induced hepatic steatosis. J Appl Toxicol. 2021 Aug;41(8):1232-1240. doi: 10.1002/jat.4109. Epub 2020 Nov 12.
• [188] Expression dynamics of pregnane X receptor-controlled genes in 3D primary human hepatocyte spheroids. Arch Toxicol. 2022 Jan;96(1):195-210. doi: 10.1007/s00204-021-03177-y. Epub 2021 Oct 23.
• [189] Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem Biol. 2011 Oct 21;6(10):1096-106.
• [190] Teriflunomide is an indirect human constitutive androstane receptor (CAR) activator interacting with epidermal growth factor (EGF) signaling. Front Pharmacol. 2018 Oct 11;9:993.
• [191] Withaferin A: A potential selective glucocorticoid receptor modulator with anti-inflammatory effect. Food Chem Toxicol. 2023 Sep;179:113949. doi: 10.1016/j.fct.2023.113949. Epub 2023 Jul 17.
• [192] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [193] 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
• [194] Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer. Ann Surg Oncol. 2011 May;18(5):1506-11. doi: 10.1245/s10434-010-1488-z. Epub 2010 Dec 24.
• [195] Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. Mol Endocrinol. 2010 Jan;24(1):33-46.
• [196] Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
• [197] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [198] Propionic acid induces mitochondrial dysfunction and affects gene expression for mitochondria biogenesis and neuronal differentiation in SH-SY5Y cell line. Neurotoxicology. 2019 Dec;75:116-122. doi: 10.1016/j.neuro.2019.09.009. Epub 2019 Sep 14.
• [199] Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
• [200] Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol. 2016 Jul 1;302:1-9. doi: 10.1016/j.taap.2016.04.007. Epub 2016 Apr 16.
• [201] Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells. Toxicol Sci. 2018 Aug 1;164(2):477-488.
• [202] Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
• [203] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [204] In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
• [205] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [206] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [207] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [208] The effect of zinc and D-penicillamine in a stable human hepatoma ATP7B knockout cell line. PLoS One. 2014 Jun 3;9(6):e98809. doi: 10.1371/journal.pone.0098809. eCollection 2014.
• [209] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [210] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [211] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [212] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [213] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [214] DNA methylation inhibits p53-mediated survivin repression. Oncogene. 2009 May 14;28(19):2046-50. doi: 10.1038/onc.2009.62. Epub 2009 Apr 13.
• [215] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [216] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [217] Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J Proteome Res. 2009 Jun;8(6):3006-19.
• [218] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [219] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [220] In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer. 2006 Mar 28;5:13.
• [221] Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
• [222] Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
• [223] Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver. Biopharm Drug Dispos. 2009 Jul;30(5):241-58.
• [224] Histamine H4 receptor agonists have more activities than H4 agonism in antigen-specific human T-cell responses. Immunology. 2007 Jun;121(2):266-75. doi: 10.1111/j.1365-2567.2007.02574.x. Epub 2007 Mar 7.
• [225] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [226] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [227] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [228] Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
• [229] The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am J Physiol Regul Integr Comp Physiol. 2007 Sep;293(3):R1400-9. doi: 10.1152/ajpregu.00781.2006. Epub 2007 Jun 13.
• [230] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [231] Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
• [232] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [233] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [234] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [235] Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res. 2007 Apr;138(2):163-9. doi: 10.1016/j.jss.2006.05.037. Epub 2007 Jan 25.
• [236] Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid. J Lipid Res. 2019 Apr;60(4):794-804. doi: 10.1194/jlr.M088880. Epub 2019 Feb 1.
• [237] Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor co-activator-1 protein. Br J Pharmacol. 2010 Oct;161(4):771-81. doi: 10.1111/j.1476-5381.2010.00900.x.
• [238] Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
• [239] Glucosamine-induced endoplasmic reticulum stress affects GLUT4 expression via activating transcription factor 6 in rat and human skeletal muscle cells. Diabetologia. 2010 May;53(5):955-65. doi: 10.1007/s00125-010-1676-1. Epub 2010 Feb 18.
• [240] AMPK activator acadesine fails to alleviate isoniazid-caused mitochondrial instability in HepG2 cells. J Appl Toxicol. 2017 Oct;37(10):1219-1224. doi: 10.1002/jat.3483. Epub 2017 May 29.
• [241] A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1 expression and mitochondrial biogenesis. PLoS One. 2012;7(10):e46753. doi: 10.1371/journal.pone.0046753. Epub 2012 Oct 3.
• [242] Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
• [243] Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
• [244] A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
• [245] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [246] Gene expression profiling of leukemia T-cells resistant to methotrexate and 7-hydroxymethotrexate reveals alterations that preserve intracellular levels of folate and nucleotide biosynthesis. Biochem Pharmacol. 2009 Apr 15;77(8):1410-7.
• [247] Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol. 2005 May 14;11(18):2748-53. doi: 10.3748/wjg.v11.i18.2748.
• [248] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [249] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [250] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [251] Differential regulation of the human MRP2 and MRP3 gene expression by glucocorticoids. J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):229-34. doi: 10.1016/j.jsbmb.2005.03.004.
• [252] Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
• [253] Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
• [254] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [255] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [256] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [257] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [258] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [259] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [260] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [261] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [262] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [263] Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. J Gen Virol. 2010 Aug;91(Pt 8):1959-1970. doi: 10.1099/vir.0.020065-0. Epub 2010 Apr 14.
• [264] Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer. Breast Cancer Res Treat. 2009 Jul;116(1):103-11. doi: 10.1007/s10549-008-0108-0. Epub 2008 Jul 10.